PDCD1 and hepatocellular carcinoma: In a nutshell, this investigation suggested whether HAMP could be considered a new biomarker for diagnosing early-stage HCC and used to predict the sensitivity and prognosis of PD-1 immunotherapy, in addition to orienting the development of new drugs.